All In MedTech

FDA Clearance Tracker · P130013-S074

WATCHMAN FLX Left Atrial Appendage (LAA) Closure Technology, WATCHMAN FLX Left Atrial Appendage Closure Device with Deli

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 16, 2025

Approved

Time to decision

180 days

Received Jan 17, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P130013-S074
Device name
WATCHMAN FLX Left Atrial Appendage (LAA) Closure Technology, WATCHMAN FLX Left Atrial Appendage Closure Device with Deli
Applicant location
Maple Grove, MN
Received
Jan 17, 2025
Decided
Jul 16, 2025
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P130013

Device type

Device class
Class III

Every decision under product code NGV

FDA's approval statement

As written in FDA's record.

Approval for expanding the indications to include patients following catheter ablation for non-valvular atrial fibrillation and to add a new post-implant drug regimen to the device labeling. The WATCHMAN FLX™ Device and the WATCHMAN FLX™ Pro Device are indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who:•Are at increased risk for stroke and systemic embolism based on CHA2DS2-VASc1 scores and are recommended for anticoagulation therapy;•Are deemed by their physicians to be suitable for anticoagulation therapy; and•Have an appropriate rationale to seek a non-pharmacologic alternative to anticoagulation therapy, taking into account the safety and effectiveness of the device compared to anticoagulation therapy.Following catheter ablation for non-valvular atrial fibrillation (concomitantly or sequentially with WATCHMAN FLX™ or WATCHMAN FLX™ Pro implantation): The WATCHMAN FLX™ and WATCHMAN FLX™ Pro devices are indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who:•Are at increased risk for stroke and systemic embolism based on CHA2DS2-VASc1 scores and are recommended for anticoagulation therapy;•Are deemed by their physicians to be suitable for anticoagulation therapy.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.